Guidelines and risk factor management

Heart

Volumn 91, Issue 4, 2005, Pages 417-418

  Primatesta, Paola ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; STATINE DERIVATIVE;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; EDITORIAL; HEART DISEASE; HIGH RISK POPULATION; HUMAN; MORTALITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; UNITED KINGDOM; GENERAL PRACTICE; NOTE; STANDARD;

CARDIOVASCULAR DISEASES; FAMILY PRACTICE; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES; RISK FACTORS;

EID: 15844397651     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.048058     Document Type: Editorial

References (16)

1. Department of Health. Saving lives: our healthier nation. London: The Stationery Office, 1999.
2. Department of Health. National service framework for coronary heart disease. Modern standards and service models. 2000. London: The Stationery Office, 2000.
3. Department of Health. National service framework for coronary heart disease. Delivering better heart services. Progress report 2003. London: The Stationery Office, 2003.
4. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85.
5. NICE. Hypertension - Management of hypertension in adults in primary care. Clinical guideline 18. London: National Institute for Clinical Excellence, 2004.
6. NICE. Management of type 2 diabetes: management of blood pressure and blood lipids. Clinical guideline H. London: National Institute for Clinical Excellence, 2002.
7. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10.
8. Martin TM, Irving JR, Sutherland M, et al. Improving secondary prevention in coronary bypass patients: closing the audit loop. Heart 2005;91:456-9.
9. Emberson JR, Whincup PH, Lawlor DA, et al. Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women. Heart 2005;91:451-5.
10. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: result from the Health Survey for England. Hypertension 2001;38:827-32.
11. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001.
12. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
13. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
14. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
15. Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activity measure: results from 7 studies and a revised scale. Diab Care 2000;23:943-50.
16. Department of Health. Delivering investment in general practice: implementing the new GMS contract. London, 2003.